Login to Your Account



Prima Biomed Backpedals After Inconclusive PFS

By Marie Powers
Staff Writer

Wednesday, September 18, 2013
in_the_clinic.jpg

Shares of Australia’s Prima Biomed Ltd. were jolted Wednesday after top-line data from the company’s Phase II study of cancer vaccine candidate Cvac showed no observed difference in estimated median progression-free survival (PFS) compared to control in epithelial ovarian cancer patients in first or second remission. On the Nasdaq Global Market – the first of the company’s public markets to react to the news – shares (NASDAQ:PBMD) fell 74 cents, or 31.3 percent, to close at $1.61.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription